frequent
infect
common
reason
physician
visit
distinguish
pattern
type
infect
suggest
immunodefici
oppos
part
normal
suscept
infect
challeng
common
caus
recurr
infect
allergi
anatom
contribut
secondari
immun
defici
unusu
burden
exposur
primari
immunodefici
pidd
much
less
common
therefor
difficult
appreci
wealth
infect
typic
seen
physician
practic
first
year
life
children
experi
six
eight
respiratori
tract
infect
per
year
tend
peak
winter
month
daycar
attend
exposur
smoker
atopi
increas
frequenc
significantli
respiratori
tract
infect
adult
somewhat
less
common
howev
three
five
respiratori
tract
infect
per
year
adult
typic
recurr
sinu
infect
pneumonia
bronchiti
common
sign
immunodefici
recogn
frequent
bacteri
infect
respiratori
track
often
harbing
antibodi
disord
common
type
primari
immunodefici
review
address
recurr
sustain
viral
infect
fewer
studi
assist
physician
identif
patient
potenti
immunodefici
review
address
unusu
viral
respiratori
tract
infect
system
viral
infect
infect
brain
mening
cutan
viral
infect
unusu
viral
infect
sign
complic
pidd
sever
excel
review
address
overal
approach
suspect
pidd
bacteri
infect
gener
highlight
therefor
review
focu
unusu
sever
viral
infect
mani
specif
genet
type
immunodefici
associ
cell
defici
diagnost
consider
differ
depend
age
patient
infant
prolong
sever
respiratori
viral
infect
evalu
scid
patient
age
dysmorph
featur
associ
featur
evalu
chromosom
delet
syndrom
state
newborn
screen
program
detect
scid
result
access
identifi
signific
cell
lymphopenia
earli
infanc
newborn
screen
significantli
improv
surviv
infant
scid
howev
signific
cell
disord
identifi
test
therefor
cell
disord
still
repres
concern
set
prolong
viral
infect
cell
enumer
often
quickest
way
screen
cell
defect
vast
major
cell
defici
condit
low
cell
number
least
low
cell
count
addit
studi
includ
prolif
studi
exclus
hiv
sequenc
panel
identifi
inborn
error
immun
manag
respiratori
tract
infect
nonscid
cell
defect
larg
support
optim
bronchodil
antivir
therapi
avail
attent
nutrit
manag
respiratori
tract
infect
scid
highli
problemat
race
replac
immun
system
viru
progress
point
return
race
highli
depend
type
transplant
donor
type
condit
type
transplant
respiratori
infect
clearli
impact
transplant
outcom
adjunct
measur
improv
respiratori
statu
sought
consider
prolong
infect
gammaherp
virus
without
hlh
cell
count
function
help
support
inform
often
genet
test
quickest
approach
hlh
disord
enumer
hlh
criteria
use
exercis
stain
bone
marrow
sensit
way
identifi
activ
hemophagocytosi
requir
diagnosi
addit
maneuv
measur
serum
surfac
marker
degranul
hlh
occur
without
underli
pidd
thu
genet
analysi
often
central
manag
nearli
alway
underli
pidd
requir
hsct
definit
therapi
wherea
hlh
due
uncommon
infect
leishmania
certain
influenza
virus
arbovirus
requir
hsct
manag
system
viral
infect
reli
avail
antivir
compound
cmv
therapi
often
begun
ganciclovir
valganciclovir
foscarnet
may
ad
viru
resist
progress
spite
adequ
ganciclovir
bone
marrow
toxic
ganciclovir
may
also
requir
chang
foscarnet
ebv
case
treat
rituximab
elimin
one
import
reservoir
viru
hlh
present
system
approach
stabil
patient
treat
underli
inflamm
essenti
risk
benefit
antivir
therapi
must
care
weigh
approach
signific
advers
event
manag
decis
often
impact
subsequ
transplant
strategi
patient
defici
complex
combin
immunodefici
secondari
disrupt
cytoskelet
rearrang
includ
inabl
properli
assembl
immun
synaps
foster
signal
cascad
requir
lymphocyt
memori
differenti
lymphocyt
migrat
tissu
also
compromis
contribut
suscept
cutan
infect
cell
count
typic
low
age
impair
memori
differenti
may
progress
age
clinic
featur
resembl
seen
syndrom
includ
low
igm
elev
ige
iga
patient
signific
atopi
infect
impair
specif
antibodi
respons
poor
memori
b
cell
respons
increas
rate
malign
elev
ige
eosinophilia
highli
suscept
cutan
viral
infect
earli
life
atop
manifest
may
domin
infecti
suscept
evolv
skin
infect
often
caus
hpv
includ
increas
risk
malign
transform
skin
lesion
herp
simplex
viru
hsv
molluscum
contagiosum
viru
varicella
zoster
viru
hsct
shown
cur
term
ev
refer
group
disord
patient
suscept
betahpv
sever
diffus
wart
strike
increas
rate
skin
carcinoma
inactiv
mutat
caus
autosom
recess
ar
ev
ever
protein
intracellular
zinc
transport
mutat
lead
alter
cell
activ
permiss
environ
hpv
interestingli
infecti
suscept
hpv
patient
present
childhood
appear
wart
lead
misdiagnosi
seborrhea
tinea
versicolor
wart
gener
wors
sunexpos
skin
reason
clear
specif
hpv
type
necessarili
seen
gener
popul
wartassoci
therapi
ev
usual
local
control
sinc
suscept
relat
hematopoiet
cell
dysfunct
role
hsct
lck
defici
caus
atyp
ev
cell
defici
well
recurr
pneumonia
sever
wart
complic
nonmelanoma
skin
cancer
date
singl
patient
lck
defici
describ
lead
uncertainti
full
spectrum
infecti
suscept
therapi
clear
reason
hsct
would
expect
cur
three
norwegian
famili
identifi
increas
viral
cutan
infect
wart
molluscum
contagiosum
well
dermat
pneumonia
four
affect
famili
member
found
share
singl
variant
gene
evid
role
cell
activ
mutat
rhoh
gene
atyp
rho
gtpase
caus
suscept
evtyp
hpv
strain
due
alter
cell
activ
home
cell
count
low
poor
skin
home
cell
increas
effector
memori
cell
set
alter
cell
receptor
signal
rhoh
defici
infecti
suscept
larg
limit
hpv
two
sibl
identifi
mice
defect
correct
transfer
wildtyp
bone
marrow
suggest
potenti
treatment
hypomorph
mutat
central
kinas
canon
pathway
lead
increas
suscept
wart
pidd
associ
fine
spars
hair
dental
defect
broad
suscept
infect
includ
opportunist
infect
spectrum
phenotyp
among
broadest
among
pidd
lymphedema
osteopetrosi
suscept
pneumocysti
fungi
mycobacteri
suscept
viral
suscept
call
associ
ikbkg
defici
inflammatori
bowel
diseas
also
common
cutan
viral
infect
common
popul
usual
domin
featur
among
pidd
section
disord
benefit
hsct
unclear
hsct
outcom
poor
mutat
yield
complex
set
phenotyp
patient
tend
monocytopenia
low
nk
b
cell
count
suscept
hpv
among
infect
laboratori
defect
progress
age
correl
increas
infect
burden
clinic
featur
includ
lymphedema
risk
malign
pulmonari
alveolar
proteinosi
infect
includ
fungal
infect
cutan
viral
infect
cutan
viral
infect
promin
featur
widerang
phenotyp
heterogen
cutan
viral
infect
genit
hpv
associ
high
rate
malign
transform
patient
gof
mutat
present
dramat
autoimmun
usual
includ
enteropathi
endocrinopathi
pictur
pronounc
infecti
suscept
suscept
candida
common
cutan
viral
infect
also
problemat
viral
infect
becom
problemat
immun
suppress
use
control
enteropathi
patient
netherton
syndrom
secondari
mutat
demonstr
congenit
ichthyosi
higher
suscept
evassoci
hpv
strain
although
netherton
syndrom
mild
humor
immun
defici
suscept
wart
seem
result
disrupt
local
respons
infect
wart
gener
control
local
measur
kinas
encod
gene
call
affect
transcript
factor
thu
impact
cell
lifespan
shown
increas
suscept
hpv
infect
well
caus
b
cell
lymphopenia
phenotyp
also
includ
suscept
ebv
cutan
viral
infect
wart
hypogammaglobulinemia
infect
myelokathexi
syndrom
caus
autosom
domin
ad
gof
mutat
lead
increas
suscept
hpv
vari
degre
pancytopenia
seen
hypogammaglobulinemia
occur
mani
patient
wart
promin
suscept
neutropenia
hypogammaglobulinemia
drive
divers
infecti
suscept
copd
cutan
carcinoma
observ
whim
treat
plerixafor
topic
control
measur
wart
wild
wart
depress
cellmedi
immun
primari
lymphedema
anogenit
dysplasia
also
correl
sever
wart
without
known
genet
etiolog
note
diagnosi
lead
evdefin
hpv
strain
infect
recent
studi
demonstr
case
patient
whose
wart
improv
quadrival
hpv
vaccin
ectoderm
dysplasia
syndrom
alter
hair
nail
gener
teeth
present
eccrin
syringofibroadenomatosi
reminisc
ev
associ
hpv
infect
idiopath
cell
lymphopenia
associ
increas
risk
cutan
wart
scid
patient
posthsct
increas
risk
wart
especi
specif
underli
mutat
manag
cutan
wart
typic
progress
low
level
remov
approach
involv
topic
therapi
freez
electrosurgeri
curettag
laser
chemic
soften
cantharidin
immun
stimul
imiquimod
antigen
bleomycin
antivir
therapi
includ
cidofovir
genit
wart
treat
conceptu
approach
manag
genit
wart
also
includ
special
consider
pregnanc
partner
screen
malign
interferon
gmcsf
use
success
papillomaviru
sever
case
therapi
unsatisfi
hsct
result
prompt
erad
though
mutat
common
chain
scid
signific
wart
posthsct
may
part
due
poor
nk
cell
function
topic
cidofovir
recent
shown
case
report
effect
patient
one
case
regress
observ
papillomaviru
vaccin
manag
includ
acyclovir
valacyclovir
famciclovir
initi
option
therapi
use
success
specif
improv
nk
cell
function
type
type
ii
interferon
use
success
model
system
small
studi
nonpidd
popul
support
use
patient
manag
focu
prevent
recurr
heal
cutan
lesion
malign
transform
relat
complex
way
persist
infect
initi
manag
molluscum
pidd
patient
control
spread
curettag
topic
therapi
salicyl
cantharidin
immun
stimul
imiquimod
topic
approach
also
use
success
retreat
week
later
often
requir
address
earli
spread
may
control
outbreak
contain
diffus
diseas
diseas
spread
despit
attempt
control
type
interferon
interferon
suggest
intralesion
immunotherapi
live
antigen
promot
contraind
pidd
patient
cell
defect
three
studi
identifi
persist
vaccinestrain
rubella
patient
moder
cell
defect
patient
ataxia
telangiectasia
wide
rang
pidd
diagnos
seen
gener
patient
suffici
cell
function
lead
rel
normal
live
immun
defici
might
even
recogn
time
mmr
vaccin
administr
manifest
larg
cutan
granuloma
although
chronic
inflamm
site
observ
persist
viru
due
compromis
cell
control
acquisit
mutat
may
impact
clearanc
propos
mechan
condit
deriv
defect
cell
nk
cell
local
tissu
immun
therefor
nearli
imposs
systemat
screen
gene
defect
relat
cutan
viral
infect
suscept
reason
start
defin
cell
quantit
function
unrev
phenotyp
suggest
pidd
whole
exom
sequenc
may
appropri
persist
infect
noroviru
result
prolong
viral
shed
symptomat
diseas
note
patient
scid
variou
secondari
immunodefici
state
seri
pediatr
pidd
patient
frequent
isol
viru
patient
scid
major
histocompat
complex
ii
defici
defici
agammaglobulinemia
repres
seri
noroviru
shed
prolong
stool
patient
immunosuppress
follow
infect
noroviru
part
multipl
infect
gi
tract
cvid
noroviru
infect
link
develop
sever
enteropathi
prolong
viral
carriag
cours
year
sever
patient
seri
clearanc
noroviru
result
normal
gi
enteropathi
concern
noroviru
great
difficulti
public
health
contain
patient
pidd
shed
prolong
period
time
risk
also
place
around
risk
noroviru
common
pathogen
gener
popul
exposur
therefor
common
noroviru
spread
moment
ill
sever
day
clinic
recoveri
vomit
fece
spread
viru
viru
live
surfac
day
alcoholbas
cleaner
complet
effect
patient
chronic
noroviru
use
bleach
clean
surfac
vigor
hand
wash
soap
water
also
effect
earli
unit
state
fda
recommend
hepat
c
posit
donor
exclud
plasma
donor
pool
result
loss
neutral
hepat
c
viral
antibodi
ivig
hepat
c
viru
hcv
infect
subsequ
report
sever
countri
due
presenc
contamin
hcv
viru
small
number
seroneg
hcv
posit
donor
sever
hepat
seen
immunodefici
patient
variabl
subset
patient
primari
hypogammaglobulinemia
observ
sever
cours
hepat
case
rapidli
fatal
younger
age
earli
treatment
ifn
associ
better
overal
outcom
follow
adopt
pcr
screen
hcv
viral
inactiv
process
pasteur
subsequ
report
ivigassoci
hcv
sinc
cautionari
tale
support
surveil
pidd
patient
risk
factor
hcv
blood
product
exposur
includ
iv
drug
use
infant
born
hcv
posit
mother
highrisk
sexual
behavior
share
person
item
potenti
blood
exposur
among
hcv
posit
individu
today
therapi
hcv
improv
outcom
compar
cohort
earli
adenoviru
enteroviru
rotaviru
isol
singl
pidd
patient
chronic
diarrhea
true
incid
known
chronic
rotaviru
infect
describ
patient
scid
agammaglobulinemia
patient
immunodefici
rotaviru
poorli
contain
within
gi
tract
investig
autopsi
activ
rotaviru
replic
identifi
liver
kidney
patient
scid
complet
digeorg
syndrom
acquiredimmunodefici
syndrom
illustr
poor
control
viral
replic
set
profound
immunodefici
import
consider
scid
associ
suscept
live
rotaviru
vaccin
inde
vaccinestrain
ill
clear
immun
reconstitut
cvid
agammaglobulinemia
rare
prolong
asymptomat
shed
vaccinestrain
polio
follow
immun
liveattenu
oral
polio
vaccin
pose
risk
immunocompromis
member
commun
addit
central
nervou
system
cn
infect
occur
agammaglobulinemia
see
main
reason
live
polio
vaccin
longer
use
usa
care
chronic
gi
viral
infect
pidd
primarili
support
optim
hydrat
nutrit
oral
administ
immunoglobulin
g
igg
demonstr
effect
therapi
chronic
infecti
diarrhea
antibodi
defici
patient
oral
igg
surviv
passag
stomach
bioavail
antivir
therapi
untest
howev
could
consid
sever
diseas
herp
simplex
enceph
gener
popul
typic
seen
newborn
typic
caus
herp
simplex
type
infect
occur
time
deliveri
infant
present
second
week
life
agit
obtund
seizur
adult
develop
herp
simplex
enceph
underli
immun
compromis
risk
factor
adultonset
herp
simplex
enceph
today
hiv
common
associ
condit
adult
herp
simplex
enceph
outsid
neonat
period
may
therefor
suggest
immunodefici
among
pidd
defect
tolllik
receptor
pathway
strongli
associ
infect
tabl
approxim
children
herp
simplex
enceph
defect
tolllik
receptor
pathway
patient
defect
may
present
childhood
adulthood
patient
kerat
describ
recognit
import
therapi
tailor
defect
known
surveil
prevent
relaps
import
sever
defect
inherit
ad
fashion
therefor
recognit
pidd
critic
manag
patient
also
surveil
famili
member
popul
studi
suggest
may
addit
defect
inherit
ar
fashion
yet
defin
key
consider
describ
tolllik
receptor
pathway
defect
due
loss
local
control
cn
antibodi
cell
respons
normal
inde
local
mucos
recurr
uncommon
consequ
test
hematopoiet
cell
reveal
typic
viral
meningoenceph
due
prolong
infect
enteroviru
strongli
suggest
specif
class
pidd
enterovirus
common
caus
viral
mening
gener
popul
manifest
acut
onset
headach
gradual
resolut
day
week
patient
agammaglobulinemia
manifest
quit
differ
children
typic
present
regress
development
mileston
ataxia
clumsi
may
note
parent
examin
featur
earli
subtl
slow
progress
lead
effort
mitig
physic
therapi
behavior
strategi
patient
known
humor
immun
defici
index
suspicion
high
workup
delay
clear
neurolog
sign
symptom
cn
infect
patient
agammaglobulinemia
poor
prognosi
phenotyp
associ
enterovir
diseas
patient
agammaglobulinemia
howev
cn
infect
common
dermatomyos
hepat
describ
progress
case
cn
infect
treatment
enterovir
diseas
includ
high
dose
immunoglobulin
avail
drug
direct
enteroviru
uniqu
subset
cn
enterovir
infect
occur
either
scid
agammaglobulinemia
liveattenu
polio
vaccin
wildtyp
polio
occur
three
serotyp
nearli
erad
even
earli
recogn
liveattenu
vaccin
could
caus
diseas
patient
hypogammaglobulinemia
could
excret
viru
year
current
circul
wildtyp
polio
seen
afghanistan
pakistan
although
viru
isol
sewag
countri
support
ongo
risk
immunodefici
individu
vaccineassoci
poliomyel
due
infect
immun
defici
individu
spread
cn
revert
vaccinestrain
viru
latter
case
even
normal
host
overt
paralyt
diseas
vaccineassoci
poliomyel
appear
acut
flaccid
paralysi
meningoenceph
immunodefici
individu
prognosi
gener
poor
test
defect
relat
herp
simplex
enceph
often
involv
genet
sequenc
although
function
analys
avail
research
basi
tabl
list
current
recogn
genet
caus
suscept
herp
simplex
enceph
diagnosi
enterovir
meningoenceph
pidd
patient
requir
specif
descript
patient
agammaglobulinemia
detect
enteroviru
surprisingli
difficult
pcr
analysi
cerebrospin
fluid
stool
less
specif
perform
howev
unusu
children
agammaglobulinemia
suggest
clinic
featur
requir
brain
biopsi
diagnosi
biopsi
tissu
test
enteroviru
pcr
patient
present
cn
enterovir
diseas
identif
immun
defici
critic
prognost
implic
strong
associ
cn
enterovir
diseas
agammaglobulinemia
support
strategi
begin
enumer
peripher
blood
b
cell
flow
cytometri
neg
secondari
immun
defici
altern
cvid
sought
reason
secondari
screen
would
measur
immunoglobulin
level
respons
vaccin
manag
herp
simplex
enceph
requir
specif
antivir
approach
well
attent
seizur
increas
intracrani
pressur
comprehens
intens
care
approach
acyclovir
deliv
intraven
cornerston
manag
one
consid
prolong
cours
oral
therapi
initi
manag
could
includ
oral
acyclovir
valacyclovir
relaps
rate
high
tolllik
receptor
pathway
defect
role
steroid
controversi
one
small
studi
immun
compet
children
support
use
betainterferon
could
argu
interferon
specif
mitig
underli
defect
tolllik
receptor
pathway
disord
manag
cn
enterovir
diseas
agammaglobulinemia
recent
review
usa
antivir
drug
avail
pocapavir
studi
may
becom
avail
high
dose
ivig
propos
therapeut
surviv
rate
remain
dismal
function
outcom
poor
viral
infect
common
caus
morbid
patient
pidd
clue
diagnosi
persist
unusu
sever
repres
signific
manag
challeng
mr
sh
ks
collect
conceiv
wrote
manuscript
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
